Xeris Pharmaceuticals | XERS - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Celltrion KRW 39.29B 7.7B 2026-03
Cspc Pharmaceutical CNY 4.01B 329.18M 2025-12
Deva Holding AS TRY 1.32B 235.77M 2023-09
Dianthus Therapeutics USD 463K 179K 2026-03
Divis Laboratories Ltd INR 16.59B 2.05B 2025-12
Eli Lilly USD 15.92B 1.33B 2025-12
Kangmei Pharma CNY 238.34M 31.95M 2026-03
Knight Therapeutics CAD 64.72M 8.91M 2025-12
Laboratorios Farma EUR 105.28M 177.08M 2025-06
Medical Developments International AUD 7.35M 7.37M 2025-06
Nektar Therapeutics USD 21.81M 8.06M 2025-12
Neuren Pharmaceuticals AUD 6.69M 6.37M 2025-06
Organigram Holdings CAD 16.41M 6.91M 2026-03
Pacira USD 126.64M 15.61M 2026-03
Perrigo USD 325.5M 36.7M 2026-03
Pharma Mar EUR 39.24M 47.46M 2026-03
Qiagen NV USD 325.27M 19.53M 2025-12
Sartorius EUR 414.5M 18.3M 2026-03
Sino Biopharmaceutical CNY 10.5B 2.53B 2024-12
Supernus Pharmaceuticals USD 129.36M 34.68M 2026-03
Tilray USD 57.47M 10.16M 2025-06
Zealand Pharma A/S 68.91M 19.35M 2025-12
Zz Pientze Pharmaceu CNY 1.16B 860.2M 2026-03